p-SCN-Bn-HOPO: A Superior Bifunctional Chelator for 89Zr ImmunoPET
نویسندگان
چکیده
منابع مشابه
Physicochemical evaluation of lyophilized formulation of p-SCN-Bn-DOTA-and p-SCN-Bn-DTPA-rituximab for NHL radioimmunotherapy
Radioimmunotherapy (RIT) of Non-Hodgkin’s lymphoma (NHL) is said to be more advantageous compared to unlabelled therapeutic antibodies. To this date, radiolabelled murine anti-CD20 mAbs, Zevalin® and Bexxar® have been approved for imaging and therapy. A preparation containing rituximab, chimeric mAb radioimmunoconjugate suitable for Lu-177 labeling, could provide better imaging and therapeutic ...
متن کاملPhysicochemical evaluation of lyophilized formulation of p-SCN-Bn-DOTA-and p-SCN-Bn-DTPA-rituximab for NHL radioimmunotherapy
Radioimmunotherapy (RIT) of Non-Hodgkin’s lymphoma (NHL) is said to be more advantageous compared to unlabelled therapeutic antibodies. To this date, radiolabelled murine anti-CD20 mAbs, Zevalin® and Bexxar® have been approved for imaging and therapy. A preparation containing rituximab, chimeric mAb radioimmunoconjugate suitable for Lu-177 labeling, could provide better imaging and therapeutic ...
متن کاملAlternative Chelator for 89Zr Radiopharmaceuticals: Radiolabeling and Evaluation of 3,4,3-(LI-1,2-HOPO)
Zirconium-89 is an effective radionuclide for antibody-based positron emission tomography (PET) imaging because its physical half-life (78.41 h) matches the biological half-life of IgG antibodies. Desferrioxamine (DFO) is currently the preferred chelator for (89)Zr(4+); however, accumulation of (89)Zr in the bones of mice suggests that (89)Zr(4+) is released from DFO in vivo. An improved chelat...
متن کاملPhysicochemical Evaluation of Lyophilized Formulation of p-SCN-Bn-DOTA- and p-SCN-Bn-DTPA-rituximab for NHL Radio Immunotherapy
Radioimmunotherapy (RIT) of Non-Hodgkin's lymphoma (NHL) is said to be more advantageous compared to unlabelled therapeutic antibodies. To this date, radiolabelled murine anti-CD20 mAbs, Zevalin® and Bexxar® have been approved for imaging and therapy. A preparation containing rituximab, chimeric mAb radio immunoconjugate suitable for Lu-177 labeling, could provide better imaging and therapeutic...
متن کاملphysicochemical evaluation of lyophilized formulation of p-scn-bn-dota-and p-scn-bn-dtpa-rituximab for nhl radioimmunotherapy
radioimmunotherapy (rit) of non-hodgkin’s lymphoma (nhl) is said to be more advantageous compared to unlabelled therapeutic antibodies. to this date, radiolabelled murine anti-cd20 mabs, zevalin® and bexxar® have been approved for imaging and therapy. a preparation containing rituximab, chimeric mab radioimmunoconjugate suitable for lu-177 labeling, could provide better imaging and therapeutic ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Bioconjugate Chemistry
سال: 2015
ISSN: 1043-1802,1520-4812
DOI: 10.1021/acs.bioconjchem.5b00572